all the latest information in
acute myeloid leukemia
, arranged by experts and healthcare professionals. Listed below are recently added expert opinions.
AACR 2020 | Can we use CH assessment to predict the risk of therapy-related myeloid neoplasms?
The AML Hub was pleased to speak to Kelly Bolton, Memorial Sloan Kettering Cancer Center, New York, US,...
FDA grants CC-486 priority review for the treatment of adult patients with AML
On May 1, 2020, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) and granted priority...
COVID-HEME forum supports hematologists during COVID-19 pandemic
COVID-HEME is a peer-to-peer forum for physicians about the care of patients with hematologic malignancies during the COVID-19...
EBMT ALWP recommendations for transplantation in patients with FLT3-ITD AML
The Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) recently...
AML World Awareness Day 2020 | The evolution of AML treatment through clinical trials
AML is a heterogenous disease, meaning that the success of given therapies depends significantly on an individual...
AML World Awareness Day 2020 | Clinical trials involving novel agents in AML
On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of...
Editorial theme | Use of checkpoint inhibitors in AML therapy
Acute myeloid leukemia (AML) is a hematological cancer characterized by uncontrolled growth of abnormal myeloblasts that infiltrate the...
VIALE-A study of venetoclax plus azacitidine meets dual primary endpoints
The VIALE-A trial (NCT02993523), comparing venetoclax plus azacitidine to placebo plus azacitidine, has met the dual primary...
Esther Natalie Oliva
Gail J. Roboz
Mark J. Levis
Tapan M. Kadia